A r t i c l e s
Disorders of myelin are among the most prevalent and diverse neuro logical disorders. They include the childhood hereditary leukodys trophies, cerebral palsy, subcortical stroke, multiple sclerosis and vascular white matter disease [1] [2] [3] . These conditions have in common the loss of oligodendrocytes, the sole myelinproducing cell of the brain and spinal cord, and each requires oligodendrocytic replace ment and remyelination as an antecedent to recovery. Myelinogenic OPCs pervade the parenchyma of both the developing and adult human brain [4] [5] [6] . We have developed strategies for isolating OPCs from fetal human brain tissue and have established that these cells efficiently remyelinate the dysmyelinated brain and spinal cord and rescue the congenitally hypomyelinated shiverer mouse [7] [8] [9] . However, the OPCs were isolated on the basis of their expression of gangliosides recognized by monoclonal antibody (mAb) A2B5 (refs. 5,10-12) , whose targets are expressed by multiple phenotypes besides OPCs, including developing neurons. We therefore used polysialated neural cell adhesion molecule (PSANCAM)-based depletion of neuronal progenitors before A2B5based immunoselection 7, 9 . Yet these studies revealed that fetal A2B5 + /PSANCAM − cells were phenotypically heterogeneous and included a large fraction of nonmyelinogenic cells restricted to astrocytic fate.
To more precisely enrich myelinogenic OPCs, here we asked whether genes recognized as selectively expressed by adult human OPCs, which are highly biased to oligodendrocyte fate, might serve as markers by which to isolate oligodendrocytebiased OPCs from the fetal brain. We had previously found that adult human A2B5 + OPCs highly overexpress mRNAs encoding both the NG2 chondroitin sulfate proteoglycan and PDGFRα 13 , suggesting the utility of each for isolating oligodendrocytebiased OPCs 14, 15 . NG2 is also expressed by pericytes, limiting its utility as a selection marker, but PDGFRα appears to be expressed specifically by OPCs in both rodents [16] [17] [18] and humans 6, 13, 19, 20 . Despite the potential of PDGFRα sorting to enrich OPCs, this strategy has not yet been tested, in part because of the incompatibility of standard dissociation techniques with PDGFRα immunoselection. To address this issue, we paired an antibody against CD140a, which recognizes a human PDGFRα ectodomain, with a compatible papainbased dissociation procedure 7 , to isolate CD140a + /PDGFRα + OPCs from the fetal human brain. We confirmed that these cells could give rise to both oligodendrocytes and astrocytes, in a BMP and serumdependent fashion, and that their oligodendrocytic progeny could robustly myelinate the hypo myelinated shiverer mouse brain. Notably, CD140a + cells exhibited more rapid and efficient myelination than did A2B5 + /PSANCAM − cells. In addition, expression profiling confirmed that CD140a + cells overexpress transcripts characteristic of OPCs. These differentially expressed genes encoded surface antigens such as CD9 (refs. 21,22) , thereby identifying alternative ectodomains by which to sort OPCs, as well as components of the WNT and NOTCH pathways, which may be critical to the turnover and fate of fetal human OPCs.
RESULTS

CD140a defines a population of OLIG2 + OPCs
In the human forebrain, OPCs are most actively generated during the second trimester. To assess the geographic distribution of CD140a + cD140a identifies a population of highly myelinogenic, migration-competent and efficiently engrafting human oligodendrocyte progenitor cells Experimental animals with myelin disorders can be treated by transplanting oligodendrocyte progenitor cells (OPCs) into the affected brain or spinal cord. OPCs have been isolated by their expression of gangliosides recognized by mAb A2B5, but this marker also identifies lineage-restricted astrocytes and immature neurons. To establish a more efficient means of isolating myelinogenic OPCs, we sorted fetal human forebrain cells for CD140a, an epitope of platelet derived growth factor receptor (PDGFR)a, which is differentially expressed by OPCs. CD140a + cells were isolated as mitotic bipotential progenitors that initially expressed neither mature neuronal nor astrocytic phenotypic markers, yet could be instructed to either oligodendrocyte or astrocyte fate in vitro. Transplanted CD140a + cells were highly migratory and robustly myelinated the hypomyelinated shiverer mouse brain more rapidly and efficiently than did A2B5 + cells. Microarray analysis of CD140a + cells revealed overexpression of the oligodendroglial marker CD9, suggesting that CD9 + /CD140a + cells may constitute an even more highly enriched population of myelinogenic progenitor cells.
A r t i c l e s cells during that period, we immunolabeled sections of human fetal forebrain (22 weeks gestational age (g.a.)) with monoclonal anti CD140a IgG, which recognizes a PDGFRα ectodomain 23 . CD140a + cells pervaded the forebrain, extending through the intermediate zone to the developing cortical mantle (Fig. 1) , with a morphology similar to that of NG2defined adult OPCs 24 . This distribution anticipates that of the adult human forebrain [4] [5] [6] . Virtually all CD140a + cells co expressed the oligodendrocyte lineage transcription factor OLIG2 (Fig. 1a) , whereas the neural stem cell-associated transcript SOX2 was coexpressed by a small fraction (Fig. 1b) . A substantial propor tion of CD140a + cells expressed KI67, a marker of actively cycling cells (Fig. 1c) . CD140a immunoreactivity did not colocalize with either astrocytic GFAP or neuronal Hu protein. Together, these data suggest that CD140a + cells comprise a pool of uncommitted OPCs that ubiquitously coexpress OLIG2.
CD140a + cells appear during second-trimester cortical expansion Appreciable numbers of CD140a + cells first began to appear in forebrain dissociates at 16 weeks g.a. At 20-22 weeks g.a., 4.8% ± 0.7% of cells within cortical dissociates, which included admixed intermediate zone and cortical mantle, were CD140a + (n = 13, s.e.m.) (Fig. 2a,b) . Over the period of 16-23 weeks, a significant correlation between the incidence of cortical CD140a + cells and gestational age (P < 0.0001, r 2 = 0.43, d.f. = 26) was noted (Fig. 2c) . In contrast, the relative incidence of CD140a + cells within the dissected ventricular and subventricular zones (VZ/SVZ) did not increase with gestational age (P = 0.57, r 2 = 0.04, d.f. = 10) (Fig. 2d) . The relatively constant proportion of CD140a + cells in the VZ/SVZ, unlike the rapidly increasing proportion of CD140a + cells in cortical dissociates (3.1% ± 0.4% versus 1.2% ± 0.1%; unpaired ttest, P = 0.012, d.f. = 37), sug gested a monotonic colonization of the developing brain by newly generated VZ/SVZderived OPCs (Fig. 2e) .
CD140a + cells include a subpopulation of A2B5 + cells A2B5 + /PSANCAM − cells derived from the fetal human brain are phenotypically heterogeneous. Although they include a myelinogenic fraction of bipotential OPCs, they also include a GFAP + fraction that appears restricted to astrocyte phenotype 7, 9 . To determine whether 
A r t i c l e s
CD140a + OPCs constitute a discrete fraction of the A2B5 + /PSA NCAM − population, we depleted dissociated fetal cells of PSA NCAM + cells by immunomagnetic sorting, and then carried out twocolor flow cytometry for A2B5 and CD140a ( Fig. 3a-c) . CD140a + cells were significantly more abundant in the A2B5 + /PSANCAM − pool than in the unsorted population from which both derived (23.2 ± 3% in A2B5 + /PSANCAM − versus 10.9 ± 3% in the initial dissociate; ttest P = 0.0324, n = 4) ( Fig. 3d) , indicating that CD140a + cells represent a subpopulation of A2B5 + cells. We next asked whether the oligodendrocytecompetent fraction of progenitors was specifically enriched in the CD140a + subpopu lation. A2B5 + /PSANCAM − and CD140a + cells, derived in parallel from the same tissue samples (n = 3), were plated into base medium supplemented with 1% plateletdepleted serum (PDFBS) and triiodothyronine (T3; 30 ng/ml), to assess their potential to differenti ate as oligodendrocytes (n = 3 samples, each done in triplicate wells/ phenotype). After 7 d, matched cultures were immunostained using mAb O4, which recognizes immature postmitotic oligodendrocytes in humans 5, 25, 26 . We found that the proportion of O4 + oligodendro cytes was substantially greater in all CD140a + fractions than in their CD140a − counterparts (n = 3 sorts) (Fig. 3e) .
Oligodendrocyte generation is restricted to CD140a + cells Because only a fraction of A2B5 + /PSANCAM − cells generate oligodendrocytes 7 , and as only some A2B5 + /PSANCAM − cells coexpress CD140a, we next asked whether oligodendrocytes arose exclusively from the CD140a + subpopulation. We used fluorescence activated cell sorting (FACS) to separately isolate CD140a + and CD140 − cells. Immediately after sorting, the CD140a + cells were uniform in size, relatively small and bright when viewed under phase microscopy. Within 24 h, most elaborated fine processes, initially as bipolar cells (Supplementary Fig. 1a ). These cells uniformly expressed CD140a (Supplementary Fig. 1b,c) and coexpressed the transcription factors OLIG2 and SOX2, which are both expressed by uncommitted glial progenitors ( Supplementary Fig. 1d,e) . In contrast, the CD140a − fraction was largely devoid of OLIG2 + cells (Supplementary Fig. 1f ). The vast majority of CD140a − cells exhibited a neuronal pheno type, expressing both βIIItubulin and the neuronal mRNA binding protein HuD (Supplementary Fig. 1g ). In addition, a subpopulation of cells in the CD140a − fraction expressed astrocytic markers, includ ing both GFAP and aquaporin 4 ( Supplementary Fig. 1h ).
To promote oligodendrocytic differentiation, we raised each of the two populations in T3supplemented media. Within 1-2 d, most CD140a + cells exhibited a bipolar progenitor morphology and expressed nuclear OLIG2. After 4 d, 36.6% ± 5% of CD140a + cells expressed the oligodendrocytic sulfatide recognized by mAb O4 (n = 13) (Fig. 4a) , compared with <0.1% of CD140a − cells (n = 7) (Fig. 4b) . CD140a + O4 + cells matured as O1 + and myelin basic protein (MBP) + oligodendrocytes by 7 d in vitro ( Fig. 4c and data not shown). In contrast, at 7 d the vast majority of CD140a − cells had matured as either βIII tubulin + neurons (63% ± 8%, n = 4 samples) or GFAP + astro cytes (6% ± 2%, n = 4) (Fig. 4d) . A subset of A2B5 + cells (21% ± 1%, n = 3), some of which coexpressed GFAP, was also noted in CD140a − cultures. Nonetheless, neither exposure to serum concentrations up to 10%, nor supplementation by 20 ng/ml IGF1, triggered the appearance of O4 + oligodendrocytes in CD140a − cultures. Overall, the percentage of O4 + cells arising from CD140a + cells under T3supplemented conditions was >200fold higher relative to their CD140a − counterparts (37% CD140a + versus 0.14% CD140a − , P < 0.0001, twotailed ttest; d.f. = 18). These data further confirmed that virtually all O4 + oligodendrocytes were produced by CD140a + OPCs.
CD140a + cells generate oligodendrocytes and astrocytes in vitro
As oligodendrocytic fate potential was restricted to CD140a + cells, we next asked whether CD140a + cells could also be induced to astrocytic fate, using serum or BMP exposure, as previously observed with adult brain-derived OPCs 13 . Addition of either serum or BMP4 after FACS induced rapid GFAP + astrocytic differentiation. Within 7 d of post sorting exposure to 0.5% PDFBS, GFAP + astrocytes increased from 8.8% to 30.7% (P = 0.002, unpaired ttest, d.f. = 5). Similarly, BMP4 exposure (50 ng/ml) yielded a dosedependent increase in astrocytes, from 8% to >40% at 4 d (P < 0.01; F = 12.4; ANOVA with Dunnett's post hoc analysis). In contrast, oligodendrocyte differentiation was inhibited by BMP4; O4 + cells declined from >30% to <5% at 4 d (P < 0.01; F = 12.7). As a result, the GFAP/O4 ratio in these cultures increased in response to BMP4, from <0.5 to >15.
Notably, CD140a + cells could be maintained as bipotential pro genitors in vitro. PDGFAA and FGF2 (each 20 ng/ml) inhibited oligodendrocytic differentiation, such that only 2.4% ± 1.2% and 4.8% ± 1.3% of PDGFAA/FGF2exposed CD140a + cells developed O4 immunoreactivity by days 4 and 7, respectively (n = 5); under these conditions, most cells remained as A2B5 + progenitors (75% ± 7%, n = 6), accompanied by the gradual appearance of GFAP + astrocytes (8.8% ± 1.9%, n = 4). FGF2 withdrawal and addition of T3 favored oligodendrocyte differentiation, increasing the incidence of O4 + cells to 13.7% ± 2.9% (P = 0.01, ttest; n = 3). In addition, astrocyte lineage commitment could be blocked by NOGGIN, a soluble competitive antagonist of the BMPs. When added to CD140a + cells in the absence of growth factors for 4 d, 100 ng/ml NOGGIN potently inhibited BMP4-induced astrocytic differentiation (P < 0.05, Tukey's post hoc test), and was also sufficient to reverse the inhibitory effect of BMP4 on oligodendrocyte commitment (21.0% ± 3% O4 + cells in BMP4 + NOGGIN, versus 4.3% ± 1% O4 + cells in BMP4 alone; P < 0.05) (Supplementary Fig. 2 ). Baseline levels of astrocytic and oligodendrocytic differentiation (8.1% ± 3% and 22.6% ± 4%, respec tively) were unaffected by 100 ng/ml NOGGIN in the absence of exogenous BMP (8.1% ± 4% GFAP + and 21.0% ± 3% O4 + ). 7 . The CD140a + cell-engrafted shiverer mice were killed at either 8 (n = 7) or 12 (n = 3) weeks of age, and their brains cryosectioned and immunostained for MBP, which is not otherwise expressed in shiverer mice. By 8 weeks, the CD140a + cell-engrafted mice exhibited substantial and wide spread forebrain myelination, in a distribution similar to but generally broader than that which we had observed using A2B5 + /PSANCAM − OPCs (Figs. 5 and 6a) . Quantification within the fimbria revealed that at 8 weeks after injection, a time point at which myelinogenesis from implanted A2B5 + /PSANCAM − fetal human OPCs is just begin ning 7 , 8% ± 3% of CD140 + cells had already differentiated as MBP + oligodendrocytes (n = 3, Fig. 5a,d) . At that time point, the majority of human cells were of oligodendrocytic lineage, such that 68% ± 14% of human nuclear antigen (hNA) + cells coexpressed OLIG2, whereas <5% of human CD140a + cells had differentiated as GFAP + astrocytes (Fig. 5c,d ). In addition, onethird persisted as NG2 + OPCs (31% ± 14%; Fig. 5b,d) ; a fraction of these remained mitotically competent, as defined by KI67 (8% ± 4%, n = 3; Fig. 5d ).
We next compared the performance at 12 weeks of CD140a + cells, in terms of both their migration and myelination competence, to that of A2B5 + /PSANCAM − cells whose in vivo myelination competence we had previously described at that time point. We assessed the efficiency of callosal axonal ensheathment by CD140a + cells, using the same transplantation and assessment protocols, source gestational ages, time of euthanization and imaging metrics that we had used previously for callosal myelination by fetal A2B5 + /PSANCAM − cells (Fig. 6) . Under these conditions, CD140a + cells continued to express A2B5, whereas <10% expressed O4. In contrast, the CD140a − /PDGFRα − fraction comprised primarily βIII-tubulin + neurons. Scale bars, 10 µm. Error bars indicate s.e.m. ***, P < 0.001; ** P < 0.01 (two-tailed t-test).
A r t i c l e s
At 12 weeks, the CD140a + cell-engrafted shiverer mice exhibited ensheathment of 26.7% ± 2.5% of all callosal axons by human MBP defined myelin (mean ± SE; n = 3 mice) (Fig. 6b-e) . Notably, in especially dense areas of donorcell engraftment, ensheathment efficiencies approached 40%. These data contrasted sharply with the average axonal myelination efficiency by A2B5 + /PSANCAM − cells at 12 weeks of 10.1% ± 2.8% (n = 6) 7 . Thus, the CD140a + cells myelinated with significantly and substantially higher efficiency at 12 weeks than did their A2B5 + /PSANCAM − counterparts (Fig. 6e,f) (n = 6; P < 0.01 by Student's ttest). Notably, despite their efficient oligodendrocytic production and myelinogenesis, engrafted CD140a + cells remained bipotential in vivo, in that they reliably generated astrocytes as well as oligodendrocytes in recipient brains (Fig. 6g,h) . Together, these findings indicate that CD140a + fetal human OPCs exhibit widespread migration and myelinogenesis in vivo, and do so more rapidly and efficiently than the larger pool of A2B5 + /PSANCAM − OPCs.
CD140a + cells express a transcript profile of OPCs
To better define the differentiation state of CD140a + human OPCs, we assessed their expression profiles relative to CD140a − cells by high throughput reverse transcription quantitative (RTq)PCR of a panel of 48 marker genes chosen as potentially predictive of glial cell fate ( Table 1) . PDGFRα mRNA was >500fold more abundant in CD140a + than in CD140a − cells (paired ttest, P = 0.013), validating both the stringency of our sorting and the use of antiCD140a as a means of isolating PDGFRα + cells. Expression of OPC and oligodendrocyte lineage markers was also higher. For instance, the CSPG4 proteogly can NG2 was overexpressed almost 50fold in CD140a + cells, and the oligodendrocyte lineage transcription factors OLIG2 and SOX10 were expressed >150fold more in CD140a + than in CD140 − cells. In addition, the progenitor profile of CD140a + cells was confirmed by their significant expression of SOX2 (refs. 27,28) (P < 0.05; Table 1 ). In contrast, neither mature oligodendrocytic genes, such as MBP, PLP (also known as PLP1), MOBP or MOG, nor those selective to astrocytes, such as GFAP or AQP4, were enriched in CD140a + OPCs ( Table 1) . Although the microglialselective transcripts CD68 and CD86 were overexpressed, migrating human glial progenitors and microglia may share these antigens 29 .
CD140a + OPCs express WNT, NOTCH and EGFR pathway genes Global transcriptional profiling revealed 408 genes significantly overexpressed by CD140a + cells (Supplementary Table 1) , including several OPC markers, in accord with our qPCR data (Supplementary Table 2 ). Gene Ontology and Ingenuity pathway analysis identi fied nervous system development (GO:0007399; P = 8.6 × 10 −5 ), neurogenesis (P = 1.6 × 10 −8 ) and schizophrenia (P = 5.0 × 10 −12 ). Gene set enrichment analysis identified the WNT, NOTCH and EGF signaling pathways as overrepresented in CD140a + cells (q = 1.7 × 10 3 , 5.1 × 10 5 and 9.3 × 10 −5 , respectively). In particular, CD140a + cells overexpressed a number of known WNT target genes (P = 0.011) (Supplementary Fig. 3 ). In addition, gene set enrichment analysis of KEGGdefined pathways identified those involved in glycan synthesis as the most differentially regulated by CD140a + cells (Supplementary Fig. 4 ).
CD9 and PDGFRa are co-expressed in fetal human progenitors Among membrane protein genes, the gene encoding CD9 was 7.4 fold enriched in CD140a + cells. We therefore asked whether human OPCs might be further separable using CD9 ectodomain-directed FACS. CD9 + cells constituted 2.75% ± 0.7% of all cells in the fetal intermediate zone and cortical plate (n = 5) and were less common in the VZ (0.51 ± 0.1%). The CD9 + pool partially overlapped with the CD140a + pool, such that around half of CD140a + OPCs expressed CD9 (49.6% ± 5%, n = 6). Of the entire dissociated pool, 2.6% ± 1.5% coexpressed CD140a and CD9 (Supplementary Fig. 5) . Indeed, used alone, CD9based sorting yielded a highly significant, 14fold enrichment in CD140a + cells relative to unsorted dissociated cells A r t i c l e s (ttest, P = 0.00002). These data suggest that CD9 identifies a distinct subpopulation of OPCs in the fetal human brain, and suggest the utility of concurrent CD9 and CD140adirected sorting to isolate a highly enriched, oligodendrocytecompetent fraction of human progenitor cells.
DISCUSSION
In this study, we used CD140a/PDGFRα expression to isolate OPCs from the fetal human brain. These cells proved robustly myelinogenic in vivo (Figs. 5 and 6 ) and were more efficient at in vivo oligodendro cytic differentiation and myelination than were matched isolates of fetal A2B5 + /PSANCAM − cells (Fig. 6) , which represent the previous standard by which OPCs were isolated for therapeutic assessment. These results suggest that, compared with fetal A2B5 + /PSANCAM − cells, fetal CD140a + cells exhibit both a higher efficiency of oligodendrocytic differentiation and more rapid initiation of myelinogenesis. Indeed, CD140a + cells myelinated with an efficiency and time course more similar to what we had previously observed with adult brain-derived A2B5 + OPCs 7 . Unlike the lat ter, however, fetal CD140a + cells migrated widely, extending as broadly throughout the brain and brainstem as their fetal A2B5 + / PSANCAM − counterparts, and with even greater penetration of both cortical and sub cortical gray matter (Fig. 6a) .
Little is known about the ontogeny of OPCs in the human forebrain. PDGFRα and NG2expressing OPCs have been described at 18 weeks g.a. in the developing telen cephalon 29, 30 , yet we found that CD140a + cells could be isolated from the fetal brain by 16 weeks g.a., and that they significantly populated the cortical mantle by 18 weeks g.a. (Figs. 1 and 2) . Previous studies have noted that O1defined oligodendrocytes appear at 28-30 weeks g.a. in the human forebrain, coincident with the initial appearance of myelin 30 . Thus, the period spanning 18-30 weeks g.a. appears to be the principal period of OPC expansion and specification in the developing human forebrain.
We previously observed that fetal human OPCs defined as A2B5 + /PSANCAM − dif ferentiated as both oligodendrocytes and astrocytes after neonatal xenograft, and could rescue the otherwise lethal shiv erer phenotype 7, 9 . Yet in the present study, we found that whereas all oligodendro cytes derived from CD140a + cells, not all A2B5 + /PSANCAM − cells were CD140 + ; rather, CD140a + cells were enriched within the population of A2B5 + /PSANCAM − cells, relative to A2B5 − cells (Fig. 3d) . Notably, only CD140a + cells were capable of oligodendrocyte differentiation in vitro (Fig. 3e) , indicating that CD140a + cells made up the entire fraction of A2B5 + /PSA NCAM − cells responsible for myelination upon xenografting. Thus, our data indicated that A2B5 + /PSANCAM − cells comprise a heterogeneous popula tion that includes both astrocyterestricted CD140a − cells and oligodendrocytecompetent CD140a + progenitors.
CD140a + cells were not restricted to the oligodendrocyte pheno type but were bipotential for astrocytes and oligodendrocytes. When stimulated in vitro with serum or BMP4, they readily exhibited astro cytic differentiation (Supplementary Fig. 2) . Thus, CD140a + fetal human OPCs behave similarly to both their adult human and rodent counterparts, which proliferate in response to PDGFAA and FGF2 (refs. 12, 31, 32) , and can develop as astrocytes in response to serum or BMPs 13, 33, 34 , yet differentiate as oligodendrocytes when raised in the absence of mitogens or BMPs. As such, CD140a + cells seem both lineally and phenotypically analogous to bipotential progenitors of the developing rodent brain 7, 33, 34 . Six fetal cortical samples of 20-22 weeks g.a. were FACS sorted for CD140a/PDGFRα immunoreactivity and immediately frozen for RNA analysis (n = 6 fetal samples). Expression of cell type-specific markers was measured by quantitative Taqman RT-PCR and compared against the matched CD140a − /PDGFRα − pool. Expression data were calculated by normalization to GAPDH, and significance was assessed by paired t-test statistics. P-values were adjusted for multiple testing effects using false-discovery rate (FDR; q-value). Mean ratio of expression and standard error ranges are shown. Significantly expressed genes at 5% FDR are boldface; significantly depleted genes are italicized. OPC-expressed genes were highly enriched in fetal CD140a + cells.
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The bipotentiality of CD140a + OPCs is of great practical import. Although they are superior to fetal A2B5defined cells in terms of their myelinogenic potential, their differentiated phenotype still depends upon the environment into which they are introduced. Whereas they might efficiently differentiate as oligodendrocytes and effectively remyelinate the congenitally hypomyelinated brain, such as in PelizaeusMerzbacher disease or cerebral palsy, their use in acute demyelinating disorders, such as multiple sclerosis or postischemic demyelination, might prove to be limited by their astroglial differen tiation in an injury environment 35 . Thus, the bilineage competence of these cells must be considered as their appropriate clinical targets are further defined.
Although human fetal CD140a + cells appear bipotential for astro cytes and oligodendrocytes both in vitro and in vivo, we cannot exclude the possibility that certain discrete CD140a + subpopulations are already restricted to one phenotype or the other. In particular, it is important to consider that even in cultures of CD140a + cells directed to the astrocyte phenotype by 5 ng/ml BMP4, some oligo dendrocytes developed (Supplementary Fig. 2 ). This suggested that the CD140a + pool, although including all bipotential progeni tors with oligodendrocyte lineage competence, might also include a fraction restricted to the oligodendrocyte phenotype. We were intrigued then to note that almost half of all CD140 + cells selec tively expressed the prooligodendroglial tetraspanin CD9 (ref. 22 ) (Supplementary Fig. 5 ). During mouse development, the pool of CD9expressing OPCs declines as myelination proceeds 22 , sug gesting the depletion of oligodendrocytebiased progenitors. Fetal human progenitors coexpressing CD9 and CD140a might therefore represent a pool of mitotically competent yet strongly oligodendrocytebiased cells that would warrant further assessment as a therapeutic vector.
Besides their potential use as transplantable cellular agents for remyelination, progenitor cells represent targets for therapeutic mobilization and induced differentiation, whether as oligodendro cytes or astrocytes. To better assess the receptors expressed by fetal CD140a + cells, and the signaling pathways by which their mobiliza tion and fate are determined, we compared their gene expression patterns to those of CD140a − cells. The oligodendrocytic bias of fetal human CD140a + cells was reflected in their antigenic and gene expression profiles, which were highly enriched in known oligoden droglial markers (PDGFRα, NG2, ST8SIA1, NKX2.2, OLIG1, OLIG2 and SOX10) ( Table 1) . These data also highlighted the importance of NOTCH, WNT and EGF signaling to both the homeostatic turnover and differentiation of CD140a + cells (Supplemental Tables 1 and 2) , and suggested that these cells actively signal to and modulate their local environment through extracellular matrix molecules and secreted ligands.
The transcriptional profile of CD140a + cells largely resembled that of adult A2B5 + OPCs 13 . Both phenotypes selectively overexpressed a number of chondroitin sulfate proteoglycans as well as their cis interacting partners. These included the heparinbinding ligand pleiotrophin (PTN), and its principal receptor, protein tyrosine phos phataseβ/ζ (PTPRZ1), a molecule important to both the turnover and fate determination of adult OPCs 13 . One target of PTRPZ1 is βcatenin 36 , which may regulate WNT signaling in oligodendroglia 37 . Indeed, this pathway may be regulated differently in fetal than in adult OPCs, as the WNT transcription factors TCF7L1 and TCF7L2 were expressed more highly in fetal CD140a + cells than in their A2B5 + adult counterparts. These data suggest a different role for the PTN PTPRZ1 interaction in regulating WNT signals in fetal than in adult human OPCs.
In summary, we have defined a method for the direct, CD140a based isolation of a highly myelinogenic pool of fetal human OPCs, which contains the entire population of cells capable of rapid oligo dendrocyte differentiation. Like fetal human A2B5 + /PSANCAM − cells, CD140a + cells robustly differentiate as myelinating oligodendro cytes when transplanted into the shiverer forebrain. Yet unlike the het erogenous population of A2B5 + /PSANCAM − cells, which includes some but not all oligodendrocytecompetent cells and is also admixed with lineagerestricted fibrous astrocytes, the CD140a + pool includes all cells that retain oligodendrocytic lineage competence. Notably, CD140a + cells differentiate and myelinate more rapidly and efficiently than do fetal A2B5 + /PSANCAM cells. The relative homogeneity, broad migration competence and rapid myelinogenesis of CD140a + cells suggest the superiority of these cells, relative to previously stud ied immunophenotypes, as therapeutic reagents for adult as well as pediatric myelin disorders.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
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